ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.
This press release includes forward-looking statements regarding the
development and commercialization of the Ibis T5000 Biosensor System, Ibis'
technology, and the revenue potential of certain government contracts. Any
statement describing Isis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement and
should be considered an at-risk statement, including those statements that
are described as Isis' goals or projections. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the process
of discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, in developing and commercializing
systems to identify infectious organisms that are effective and
commercially attractive, and in the endeavor of building a business around
such products. Isis' forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its results
to differ materially from those expressed or implied by such
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved